Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
Status:
Unknown status
Trial end date:
2020-12-17
Target enrollment:
Participant gender:
Summary
The study is a single-arm, multi-center, open-label clinical trial. The study aims to expand
the sample size based on the fixed dose recommended by the results of previous dose
exploration studies in order to further evaluate the study drug's efficacy and safety.
Phase:
Phase 2
Details
Lead Sponsor:
Hangzhou ACEA Pharmaceutical Research Co., Ltd. Hangzhou ACEA Pharmaceutical Research Co.,Ltd.
Collaborators:
Acea Bio (Hangzhou) Co., Ltd. Guangdong General Hospital Guangdong Provincial People's Hospital